Advertisement

Medical Treatment of GERD

  • Charles Muller
  • Natalie Tapaskar
  • Robert T. KavittEmail author
Chapter

Abstract

Medical therapy for gastroesophageal reflux disease (GERD) may be approached in two ways: directly applied to correct the underlying mechanisms involved in disease pathogenesis or alternatively applied to symptom severity in a “step-up” or “step-down” fashion. Mechanistic approaches to therapy can further be subdivided into directing therapy at decreasing the frequency of transient lower esophageal sphincter relaxation to minimize esophageal exposure to gastric acid or more commonly neutralizing or suppressing gastric acidity, thereby rendering refluxed materials less caustic to esophageal mucosa. Pharmacologic agents for patients with persistent symptoms despite lifestyle interventions include nonabsorbable agents, antisecretory agents, prokinetic agents, and inhibitors of transient lower esophageal sphincter relaxations (TLESRs).

Keywords

Gastroesophageal reflux disease GERD PPI (proton pump inhibitor) Acid reflux Antacids Histamine-2-receptor antagonists GERD in pregnancy 

Notes

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118(2):S9–S31.PubMedCrossRefGoogle Scholar
  2. 2.
    Kroch DA, Madanick RD. Medical treatment of gastroesophageal reflux disease. World J Surg. 2017;41(7):1678–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Kahrilas PJ, Shaheen NJ, Vaezi MF, Institute AGA, Committee CPaQM. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1392–413, 413.e1–5PubMedCrossRefGoogle Scholar
  4. 4.
    Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28.. quiz 29PubMedCrossRefGoogle Scholar
  5. 5.
    Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166(9):965–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Dua K, Bardan E, Ren J, Sui Z, Shaker R. Effect of chronic and acute cigarette smoking on the pharyngo-upper oesophageal sphincter contractile reflex and reflexive pharyngeal swallow. Gut. 1998;43(4):537–41.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Stanciu C, Bennett JR. Smoking and gastro-oesophageal reflux. Br Med J. 1972;3(5830):793–5.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000;95(12):3374–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Grande L, Monforte R, Ros E, Toledo-Pimentel V, Estruch R, Lacima G, et al. High amplitude contractions in the middle third of the oesophagus: a manometric marker of chronic alcoholism? Gut. 1996;38(5):655–62.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Cranley JP, Achkar E, Fleshler B. Abnormal lower esophageal sphincter pressure responses in patients with orange juice-induced heartburn. Am J Gastroenterol. 1986;81(2):104–6.PubMedGoogle Scholar
  11. 11.
    Thomas FB, Steinbaugh JT, Fromkes JJ, Mekhjian HS, Caldwell JH. Inhibitory effect of coffee on lower esophageal sphincter pressure. Gastroenterology. 1980;79(6):1262–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Wright LE, Castell DO. The adverse effect of chocolate on lower esophageal sphincter pressure. Am J Dig Dis. 1975;20(8):703–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Nebel OT, Castell DO. Inhibition of the lower oesophageal sphincter by fat–a mechanism for fatty food intolerance. Gut. 1973;14(4):270–4.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kadakia SC, Kikendall JW, Maydonovitch C, Johnson LF. Effect of cigarette smoking on gastroesophageal reflux measured by 24-h ambulatory esophageal pH monitoring. Am J Gastroenterol. 1995;90(10):1785–90.PubMedGoogle Scholar
  15. 15.
    Pehl C, Pfeiffer A, Wendl B, Kaess H. The effect of decaffeination of coffee on gastro-oesophageal reflux in patients with reflux disease. Aliment Pharmacol Ther. 1997;11(3):483–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Wendl B, Pfeiffer A, Pehl C, Schmidt T, Kaess H. Effect of decaffeination of coffee or tea on gastro-oesophageal reflux. Aliment Pharmacol Ther. 1994;8(3):283–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Murphy DW, Castell DO. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol. 1988;83(6):633–6.PubMedGoogle Scholar
  18. 18.
    Allen ML, Mellow MH, Robinson MG, Orr WC. The effect of raw onions on acid reflux and reflux symptoms. Am J Gastroenterol. 1990;85(4):377–80.PubMedGoogle Scholar
  19. 19.
    Iwakiri K, Kobayashi M, Kotoyori M, Yamada H, Sugiura T, Nakagawa Y. Relationship between postprandial esophageal acid exposure and meal volume and fat content. Dig Dis Sci. 1996;41(5):926–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Hamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988;33(5):518–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Pollmann H, Zillessen E, Pohl J, Rosemeyer D, Abucar A, Armbrecht U, et al. Effect of elevated head position in bed in therapy of gastroesophageal reflux. Z Gastroenterol. 1996;34 Suppl 2:93–9.Google Scholar
  22. 22.
    Harvey RF, Gordon PC, Hadley N, Long DE, Gill TR, Macpherson RI, et al. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet. 1987;2(8569):1200–3.PubMedCrossRefGoogle Scholar
  23. 23.
    Duroux P, Bauerfeind P, Emde C, Koelz HR, Blum AL. Early dinner reduces nocturnal gastric acidity. Gut. 1989;30(8):1063–7.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Orr WC, Harnish MJ. Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Aliment Pharmacol Ther. 1998;12(10):1033–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639–49.PubMedCrossRefGoogle Scholar
  26. 26.
    Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340–8.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211.PubMedCrossRefGoogle Scholar
  28. 28.
    Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013;108(3):376–82.PubMedCrossRefGoogle Scholar
  29. 29.
    Mathus-Vliegen LM, Tytgat GN. Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. Eur J Gastroenterol Hepatol. 1996;8(7):635–40.PubMedGoogle Scholar
  30. 30.
    Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37(11):1246–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Mathus-Vliegen EM, van Weeren M, van Eerten PV. Los function and obesity: the impact of untreated obesity, weight loss, and chronic gastric balloon distension. Digestion. 2003;68(2–3):161–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol. 1999;34(4):337–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol. 1996;31(11):1047–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Singh M, Lee J, Gupta N, Gaddam S, Smith BK, Wani SB, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring). 2013;21(2):284–90.CrossRefGoogle Scholar
  35. 35.
    Sontag SJ. The medical-management of reflux esophagitis – role of antacids and acid inhibition. Gastroenterol Clin N. 1990;19(3):683–712.Google Scholar
  36. 36.
    Decktor DL, Robinson M, Maton PN, Lanza FL, Gottlieb S. Effects of aluminum/magnesium hydroxide and calcium carbonate on esophageal and gastric pH in subjects with heartburn. Am J Ther. 1995;2(8):546–52.PubMedCrossRefGoogle Scholar
  37. 37.
    Decktor DL, Robinson M, Gottlieb S. Comparative effects of liquid antacids on esophageal and gastric pH in patients with heartburn. Am J Ther. 1995;2(7):481–6.PubMedCrossRefGoogle Scholar
  38. 38.
    McRorie JW Jr, Gibb RD, Miner PB Jr. Evidence-based treatment of frequent heartburn: the benefits and limitations of over-the-counter medications. J Am Assoc Nurse Pract. 2014;26(6):330–9.PubMedGoogle Scholar
  39. 39.
    Maton PN, Burton ME. Antacids revisited – a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57(6):855–70.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Collings KL, Rodriguez-Stanley S, Proskin HM, Robinson M, Miner PB. Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control. Aliment Pharm Therap. 2002;16(12):2029–35.CrossRefGoogle Scholar
  41. 41.
    Robinson M, Rodriguez-Stanley S, Miner PB, McGuire AJ, Fung K, Ciociola AA. Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn. Aliment Pharm Therap. 2002;16(3):435–43.CrossRefGoogle Scholar
  42. 42.
    Grove O, Bekker C, Jeppe-Hansen MG, Karstoft E, Sanchez G, Axelsson CK, et al. Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand J Gastroenterol. 1985;20(4):457–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol. 1989;24(4):401–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983;28(6):559–63.PubMedCrossRefGoogle Scholar
  45. 45.
    Petrokubi RJ, Jeffries GH. Cimetidine versus antacid in scleroderma with reflux esophagitis – randomized double-blind controlled-study. Gastroenterology. 1979;77(4):691–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Cucchiara S, Staiano A, Romaniello G, Capobianco S, Auricchio S. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child. 1984;59(9):842–7.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Houcke P, Maffioli C, Corallo J, Bouxin-Sauzet A, Martin AL. Comparison of the effects of Rocgel and anti-H2 on the symptomatology of gastroesophageal reflux without esophagitis. Ann Gastroenterol Hepatol (Paris). 1995;31(4):264–7.Google Scholar
  48. 48.
    Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1–9.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012;25(5):373–80.PubMedCrossRefGoogle Scholar
  50. 50.
    Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharm Therap. 2010;32(3):334–43.CrossRefGoogle Scholar
  51. 51.
    Kessing BF, Conchillo JM, Bredenoord AJ, Smout AJPM, Masclee AAM. Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease. Aliment Pharm Therap. 2011;33(6):650–61.CrossRefGoogle Scholar
  52. 52.
    Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52(10):1397–402.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15(3):355–70.PubMedCrossRefGoogle Scholar
  55. 55.
    Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004;16(5):441–3.PubMedCrossRefGoogle Scholar
  56. 56.
    Kung YM, Hsu WH, Wu MC, Wang JW, Liu CJ, Su YC, et al. Recent advances in the pharmacological management of gastroesophageal reflux disease. Dig Dis Sci. 2017;62(12):3298–316.PubMedCrossRefGoogle Scholar
  57. 57.
    Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009;4:CD004275.Google Scholar
  58. 58.
    Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18(6):370–3.PubMedCrossRefGoogle Scholar
  59. 59.
    Zhao F, Wang S, Liu L, Wang Y. Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis. Int J Clin Pharmacol Ther. 2016;54(10):761–70.PubMedCrossRefGoogle Scholar
  60. 60.
    Gyawali CP. Proton pump inhibitors in gastroesophageal reflux disease: friend or foe. Curr Gastroenterol Rep. 2017;19(9):46.PubMedCrossRefGoogle Scholar
  61. 61.
    Larsson H, Carlsson E, Junggren U, Olbe L, Sjostrand SE, Skanberg I, et al. Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology. 1983;85(4):900–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2(2):132–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Klinkenberg-Knol EC, Jansen JM, Festen HP, Meuwissen SG, Lamers CB. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (London, England). 1987;1(8529):349–51.CrossRefGoogle Scholar
  64. 64.
    Lauritsen K, Rune SJ, Bytzer P, Kelbaek H, Jensen KG, Rask-Madsen J, et al. Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med. 1985;312(15):958–61.PubMedCrossRefGoogle Scholar
  65. 65.
    Walan A, Bader JP, Classen M, Lamers CB, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989;320(2):69–75.PubMedCrossRefGoogle Scholar
  66. 66.
    Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996;31(1):9–28.PubMedCrossRefGoogle Scholar
  67. 67.
    Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095.Google Scholar
  68. 68.
    Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Lam SK, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol. 2005;11(26):4067–77.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol. 2005;11(28):4291–9.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–810.PubMedCrossRefGoogle Scholar
  71. 71.
    Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.PubMedCrossRefGoogle Scholar
  72. 72.
    De Graef J, Woussen-Colle MC. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology. 1986;91(2):333–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997;17(1):22–37.PubMedGoogle Scholar
  74. 74.
    Howden CW. Review article: immediate-release proton-pump inhibitor therapy–potential advantages. Aliment Pharmacol Ther. 2005;22(Suppl 3):25–30.PubMedCrossRefGoogle Scholar
  75. 75.
    Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;21(12):1467–74.PubMedCrossRefGoogle Scholar
  76. 76.
    Howden CW, Ballard ED, Koch FK, Gautille TC, Bagin RG. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. J Clin Gastroenterol. 2009;43(4):323–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Walker D, Ng Kwet Shing R, Jones D, Gruss HJ, Regula J. Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec. PLoS One. 2015;10(2):e0116308.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4(12):1452–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther. 2003;18(6):559–68.PubMedCrossRefGoogle Scholar
  80. 80.
    Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001;15(11):1729–36.PubMedCrossRefGoogle Scholar
  81. 81.
    Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther. 2003;17(10):1237–45.PubMedCrossRefGoogle Scholar
  82. 82.
    Mathews S, Reid A, Tian C, Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol. 2010;3:11–6.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101–33.PubMedCrossRefGoogle Scholar
  84. 84.
    Simon B, Muller P, Pascu O, Gatz G, Sander P, Huber R, et al. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2003;15(7):791–9.PubMedGoogle Scholar
  85. 85.
    Mulder CJJ, Westerveld BD, Smit JM, Pool MO, Otten MH, Tan TG, et al. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. Eur J Gastroen Hepat. 2002;14(6):649–56.CrossRefGoogle Scholar
  86. 86.
    Thomson A. Impact of PPIs on patient focused symptomatology in GERD. Ther Clin Risk Manag. 2008;4(6):1185–200.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Scholten T, Teutsch I, Bohuschke M, Gatz G. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Invest. 2007;27(4):287–96.CrossRefGoogle Scholar
  88. 88.
    Morelli G, Chen H, Rossiter G, Rege B, Lu Y. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther. 2011;33(7):845–54.PubMedCrossRefGoogle Scholar
  89. 89.
    Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, et al. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis – the results of two double-blind studies. Aliment Pharmacol Ther. 2011;33(2):203–12.PubMedCrossRefGoogle Scholar
  90. 90.
    Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Scand J Gastroenterol. 1999;34(4):341–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion. 2003;67(1–2):1–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Wu MS, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38(2):190–201.PubMedCrossRefGoogle Scholar
  93. 93.
    Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR: a review. Ann Med. 2011;43(5):366–74.PubMedCrossRefGoogle Scholar
  94. 94.
    Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor–evidence for dosing flexibility. Aliment Pharmacol Ther. 2009;29(8):824–33.PubMedCrossRefGoogle Scholar
  95. 95.
    Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106(3):421–31.PubMedCrossRefGoogle Scholar
  96. 96.
    Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012;10(3):247–53.PubMedCrossRefGoogle Scholar
  97. 97.
    Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121(5):1095–100.PubMedCrossRefGoogle Scholar
  98. 98.
    Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003;98(9):1940–4.PubMedCrossRefGoogle Scholar
  99. 99.
    Tsuzuki T, Okada H, Kawahara Y, Takenaka R, Nasu J, Ishioka H, et al. Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. World J Gastroenterol. 2011;17(11):1480–7.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616–20.PubMedCrossRefGoogle Scholar
  101. 101.
    Miner PB Jr, McKean LA, Gibb RD, Erasala GN, Ramsey DL, McRorie JW. Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors. Aliment Pharmacol Ther. 2010;31(8):846–51.PubMedGoogle Scholar
  102. 102.
    Miehlke S, Lobe S, Madisch A, Kuhlisch E, Laass M, Grossmann D, et al. Intragastric acidity during administration of generic omeprazole or esomeprazole – a randomised, two-way crossover study including CYP2C19 genotyping. Aliment Pharm Therap. 2011;33(4):471–6.CrossRefGoogle Scholar
  103. 103.
    Kushner PR, Peura DA. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect? Adv Ther. 2011;28(5):367–88.PubMedCrossRefGoogle Scholar
  104. 104.
    Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20(4):413–21.PubMedCrossRefGoogle Scholar
  105. 105.
    Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol. 2006;4(1):50–6.PubMedCrossRefGoogle Scholar
  106. 106.
    Fass R, Murthy U, Hayden CW, Malagon IB, Pulliam G, Wendel C, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000;14(12):1595–603.PubMedCrossRefGoogle Scholar
  107. 107.
    Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55(10):1398–402.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Habu Y, Maeda K, Kusuda T, Yoshino T, Shio S, Yamazaki M, et al. “Proton-pump inhibitor-first” strategy versus “step-up” strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J Gastroenterol. 2005;40(11):1029–35.PubMedCrossRefGoogle Scholar
  109. 109.
    Mine S, Iida T, Tabata T, Kishikawa H, Tanaka Y. Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2005;20(9):1365–70.PubMedCrossRefGoogle Scholar
  110. 110.
    Bjornsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945–54.PubMedCrossRefGoogle Scholar
  111. 111.
    MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. Integr Pharm Res Pract. 2018;7:41–52.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (London, England). 2009;374(9694):989–97.CrossRefGoogle Scholar
  113. 113.
    Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.PubMedCrossRefGoogle Scholar
  114. 114.
    Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48.PubMedCrossRefGoogle Scholar
  115. 115.
    Yang YX. Chronic proton pump inihibitor therapy and calcium metabolism. Curr Gastroenterol Rep. 2012;14(6):473–9.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.PubMedCrossRefGoogle Scholar
  117. 117.
    Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21–5.PubMedCrossRefGoogle Scholar
  118. 118.
    Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.PubMedCrossRefGoogle Scholar
  119. 119.
    Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765–71.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93–101.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, Group CR. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161–8.PubMedCrossRefGoogle Scholar
  123. 123.
    Khalili H, Huang ES, Jacobson BC, Camargo CA, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18; quiz 19PubMedCrossRefGoogle Scholar
  125. 125.
    Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.PubMedCrossRefGoogle Scholar
  126. 126.
    Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904.PubMedCrossRefGoogle Scholar
  127. 127.
    Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95–101.PubMedCrossRefGoogle Scholar
  128. 128.
    Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361–9.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15.PubMedCrossRefGoogle Scholar
  130. 130.
    Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153–63.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3(2):E166–71.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702–10.PubMedCrossRefGoogle Scholar
  134. 134.
    Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381–5.PubMedCrossRefGoogle Scholar
  136. 136.
    Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545–53.PubMedCrossRefGoogle Scholar
  137. 137.
    Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001;15(3):511–21.PubMedCrossRefGoogle Scholar
  138. 138.
    Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4(1):50–4.PubMedCrossRefGoogle Scholar
  139. 139.
    Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12(1):99–104.PubMedCrossRefGoogle Scholar
  140. 140.
    Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.PubMedCrossRefGoogle Scholar
  141. 141.
    Lewis SJ, Franco S, Young G, O’Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557–61.PubMedCrossRefGoogle Scholar
  142. 142.
    Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis. 1985;151(2):355–61.PubMedCrossRefGoogle Scholar
  143. 143.
    Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a Crossover Trial. Gastroenterology. 2015;149(4):883–5.e9.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.PubMedCrossRefGoogle Scholar
  146. 146.
    Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.PubMedCrossRefGoogle Scholar
  147. 147.
    Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.PubMedCrossRefGoogle Scholar
  148. 148.
    Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):784–91.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87(7):636–42.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Leonard AD, Ho KM, Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study. Intern Med J. 2012;42(5):591–4.PubMedCrossRefGoogle Scholar
  151. 151.
    Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992;33(5):617–21.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.PubMedCrossRefGoogle Scholar
  153. 153.
    Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167(9):950–5.PubMedCrossRefGoogle Scholar
  154. 154.
    Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–77.PubMedCrossRefGoogle Scholar
  157. 157.
    Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337–44.PubMedCrossRefGoogle Scholar
  158. 158.
    Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis. 2012;54(1):33–42.PubMedCrossRefGoogle Scholar
  159. 159.
    Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Badiola N, Alcalde V, Pujol A, Münter LM, Multhaup G, Lleó A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837.PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419–28.PubMedCrossRefGoogle Scholar
  162. 162.
    Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.PubMedCrossRefGoogle Scholar
  163. 163.
    Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol. 2017;112(12):1802–8.PubMedCrossRefGoogle Scholar
  164. 164.
    Lochhead P, Hagan K, Joshi AD, Khalili H, Nguyen LH, Grodstein F, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology. 2017;153(4):971–9.e4.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–42.PubMedCrossRefGoogle Scholar
  166. 166.
    Bezwoda W, Charlton R, Bothwell T, Torrance J, Mayet F. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med. 1978;92(1):108–16.PubMedGoogle Scholar
  167. 167.
    Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12(1):83–98.PubMedCrossRefGoogle Scholar
  168. 168.
    Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291–5.PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56(8):2349–53.PubMedCrossRefGoogle Scholar
  170. 170.
    Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821–9.e1.PubMedCrossRefGoogle Scholar
  171. 171.
    Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288–92.PubMedCrossRefGoogle Scholar
  172. 172.
    Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6.PubMedCrossRefGoogle Scholar
  173. 173.
    Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–41.PubMedCrossRefGoogle Scholar
  174. 174.
    Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405–13.PubMedCrossRefGoogle Scholar
  175. 175.
    Bassey OO. Pregnancy heartburn in Nigerians and Caucasians with theories about aetiology based on manometric recordings from the oesophagus and stomach. Br J Obstet Gynaecol. 1977;84(6):439–43.PubMedCrossRefGoogle Scholar
  176. 176.
    Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med. 1995;27(1):67–70.PubMedCrossRefGoogle Scholar
  177. 177.
    Rey E, Rodriguez-Artalejo F, Herraiz MA, Sanchez P, Alvarez-Sanchez A, Escudero M, et al. Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol. 2007;102(11):2395–400.PubMedCrossRefGoogle Scholar
  178. 178.
    Marrero JM, Goggin PM, de Caestecker JS, Pearce JM, Maxwell JD. Determinants of pregnancy heartburn. Br J Obstet Gynaecol. 1992;99(9):731–4.PubMedCrossRefGoogle Scholar
  179. 179.
    Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am. 2003;32(1):235–61.PubMedCrossRefGoogle Scholar
  180. 180.
    Tsai CC, Tey SL, Chang LC, Su YT, Lin KJ, Huang SC. Estradiol mediates relaxation of porcine lower esophageal sphincter. Steroids. 2018;136:56–62.PubMedCrossRefGoogle Scholar
  181. 181.
    Ali RA, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol. 2007;21(5):793–806.PubMedCrossRefGoogle Scholar
  182. 182.
    Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005;22(9):749–57.PubMedCrossRefGoogle Scholar
  183. 183.
    Richter JE. Heartburn, nausea, and vomiting during pregnancy. Pregnancy in gastrointestinal disorders, ACG Monograph American College of Physicians. 2007, p. 18–25.Google Scholar
  184. 184.
    Ching CK, Lam SK. Antacids. Indications and limitations. Drugs. 1994;47(2):305–17.PubMedCrossRefGoogle Scholar
  185. 185.
    Phupong V, Hanprasertpong T. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev. 2015;(9):CD011379.Google Scholar
  186. 186.
    Eltonsy S, Martin B, Ferreira E, Blais L. Systematic procedure for the classification of proven and potential teratogens for use in research. Birth Defects Res A Clin Mol Teratol. 2016;106(4):285–97.PubMedCrossRefGoogle Scholar
  187. 187.
    Undeland KA, Hausken T, Svebak S, Aanderud S, Berstad A. Wide gastric antrum and low vagal tone in patients with diabetes mellitus type 1 compared to patients with functional dyspepsia and healthy individuals. Dig Dis Sci. 1996;41(1):9–16.PubMedCrossRefGoogle Scholar
  188. 188.
    Ruigómez A, García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Wallander MA, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol. 1999;150(5):476–81.PubMedCrossRefGoogle Scholar
  189. 189.
    Larson JD, Patatanian E, Miner PB, Rayburn WF, Robinson MG. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol. 1997;90(1):83–7.PubMedCrossRefGoogle Scholar
  190. 190.
    Parker S, Schade RR, Pohl CR, Gavaler JS, Van Thiel DH. Prenatal and neonatal exposure of male rat pups to cimetidine but not ranitidine adversely affects subsequent adult sexual functioning. Gastroenterology. 1984;86(4):675–80.PubMedGoogle Scholar
  191. 191.
    Savarino V, Giusti M, Scalabrini P, Bessarione D, Magnolia MR, Percario G, et al. Famotidine has no significant effect on gonadal function in man. Gastroenterol Clin Biol. 1988;12(1):19–22.PubMedGoogle Scholar
  192. 192.
    Morton DM. Pharmacology and toxicology of nizatidine. Scand J Gastroenterol Suppl. 1987;136:1–8.PubMedCrossRefGoogle Scholar
  193. 193.
    Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci. 2002;47(7):1526–9.PubMedCrossRefGoogle Scholar
  194. 194.
    Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009;104(6):1541–5; quiz 0, 6PubMedCrossRefGoogle Scholar
  195. 195.
    Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363(22):2114–23.PubMedCrossRefGoogle Scholar
  196. 196.
    Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med. 1990;323(24):1672–80.PubMedCrossRefGoogle Scholar
  197. 197.
    Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–11.PubMedPubMedCentralCrossRefGoogle Scholar
  198. 198.
    Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29(1):35–50.PubMedCrossRefGoogle Scholar
  199. 199.
    Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Charles Muller
    • 1
  • Natalie Tapaskar
    • 2
  • Robert T. Kavitt
    • 3
    • 4
    Email author
  1. 1.Department of Medicine, Section of Gastroenterology, Hepatology, and NutritionUniversity of ChicagoChicagoUSA
  2. 2.Department of MedicineUniversity of ChicagoChicagoUSA
  3. 3.Center for Esophageal Diseases, Department of Medicine, Section of Gastroenterology, Hepatology, and NutritionUniversity of ChicagoChicagoUSA
  4. 4.University of Chicago MedicineChicagoUSA

Personalised recommendations